2m 2m 2m 2m 2m 2m 2m
Todos Medical (TOMDF)
OTC
$0.000001$0.00 (0.00%)
Price as of Jun 01, 2026- N/AMarket Cap
- 0.00%1-Year Change
- Diagnostics & ResearchIndustry
Todos Medical (TOMDF)
$0.000001$0.00 (0.00%)
Annual
Quarterly
12/31/2021 | 12/31/2020 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 12.2M +134.88% | 5.2M N/A | |
Cost of Revenue | 7.8M +105.53% | 3.8M N/A | |
Gross Profit | 4.4M +215.55% | 1.4M N/A | |
Sales and Marketing Expense | 3.5M +13.83% | 3.1M N/A | |
Research and Development Expense | -824,000 -91.65% | -9.9M N/A | |
Depreciation and Amortization Expense | 763,000 +694.79% | 96,000 N/A | |
Total Operating Expenses | 9.4M +243.13% | 2.7M N/A | |
Operating Profit | -9.3M -34.89% | -14.3M N/A | |
Interest Income | -1.7M +38.17% | -1.2M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | -1.7M +38.17% | -1.2M N/A | |
Total Nonoperating Income and Expense | 378,000 N/A | N/A N/A | |
Income before Taxes | -9.3M -34.89% | -14.3M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | 1.5M N/A | N/A N/A | |
Net Income | -43.3M +45.48% | -29.8M N/A | |
Net Income from Continuing Operations Applicable to Common | -43.3M +45.48% | -29.8M N/A | |
Basic EPS and Net Income | -0.06 -45.45% | -0.11 N/A | |
Diluted EPS and Net Income | -0.06 -45.45% | -0.11 N/A | |
Basic Weighted Average Shares | 679.6M +162.21% | 259.2M N/A | |
Diluted Weighted Average Shares | 679.6M +162.21% | 259.2M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 189,000 -79.79% | 935,000 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 189,000 -79.79% | 935,000 N/A | |
Total Current Assets | 4.7M +92.49% | 2.5M N/A | |
Accumulated Depreciation | 485,000 +132.06% | 209,000 N/A | |
Property and Plant and Equipment and Net | 2.0M +2.30% | 2.0M N/A | |
Total Long-Term Assets | 10.4M +192.19% | 3.6M N/A | |
Total Assets | 15.1M +151.54% | 6.0M N/A | |
Income Taxes Payable | 315,000 N/A | N/A N/A | |
Total Short-Term Debt | 2.0M +20.99% | 1.7M N/A | |
Total Current Liabilities | 9.0M +11.04% | 8.1M N/A | |
Total Long-Term Debt | 25.4M +325.92% | 6.0M N/A | |
Total Long-Term Liabilities | 30.4M +239.26% | 9.0M N/A | |
Total Liabilities | 9.0M +11.04% | 8.1M N/A | |
Retained Earnings | -90.6M +91.61% | -47.3M N/A | |
Total Stockholders Equity | -24.2M +119.89% | -11.0M N/A | |
Total Shares Outstanding | 975.6M +159.25% | 376.3M N/A | |
Cash Flow | |||
Cash from Operating Activities | -11.2M +338.78% | -2.6M N/A | |
Capital Expenditures | 1.1M -45.96% | 2.0M N/A | |
Cash from Investing Activities | -4.7M +30.14% | -3.6M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 15.2M +114.10% | 7.1M N/A | |
Financials Ratio | |||
Gross Margin | 35.84% +34.35% | 26.68% N/A | |
Operating Margin | -75.93% -72.28% | -273.88% N/A | |
Return on Assets | -410.09% -57.99% | -976.18% N/A | |
Return on Equity | 245.94% -28.71% | 345.00% N/A | |
Revenue Growth | 134.88% N/A | N/A N/A | |
Current Ratio | 0.53 +73.35% | 0.30 N/A | |
Cash Ratio | 0.02 -81.79% | 0.12 N/A | |
Debt-to-Equity Ratio | -1.13 +63.34% | -0.69 N/A | |
Debt-to-Assets Ratio | 1.81 +42.79% | 1.27 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow